Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
StroKE34: intra-arterial CD34+ cells in acute ischemic stroke
2025-520850-13-00Phase 2Authorised
- Sponsor
- ULS Coimbra
- Start
- Jan 2025
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of Strimvelis in ischemic stroke (2 arms), sponsored by ULS Coimbra. Primary endpoints: Infarct volume at three months after ischemic stroke and Volume de enfarte aos três meses após AVC isquémico. Planned start Jan 2025; status: authorised.
02
Drugs
Strimvelis
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on 2025-520850-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520850-13-00.